Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bile Duct Cancer: early-phase trial registry
7 of 12 indexed Bile Duct Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Bile Duct Cancer: 12 US clinical trials tracked, 7 recruiting.
Bile Duct Cancer is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition bile-duct-cancer
OPEN 7 | RECR 58% | LATE 0 | EARLY 7 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)
Bile Duct Cancer lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bile Duct Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bile Duct Cancer is recruiting above its size-band peers.
7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Bile Duct Cancer research.
National Cancer Institute (NCI) accounts for 3 of 12 trials (25%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Bile Duct Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 67 among the 11 trials that report a genuine target (sentinel values excluded). 7 of those (63.6%) plan for fewer than 100 participants.
-
Bile Duct Cancer research is mostly interventional.
9 interventional and 3 observational studies make up this index (75% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Integrated Cancer Repository for Cancer Research
University of Nebraska
NCT02012699
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Cancer Institute (NCI)
NCT01915225
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Orlando Health
NCT06340620
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05286814
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
NCT05849480
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Nataliya Uboha
NCT06048133
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
NCT05655949
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics
NCT05712356
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
University of Pittsburgh
NCT01640522
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
Mauna Kea Technologies
NCT00779688
Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers
University of Southern California
NCT00183846
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Bile Duct Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bile Duct Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bile Duct Cancer page
12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Bile Duct Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Bile Duct Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bile Duct Cancer condition card totals 12 registered trials; most-linked intervention Gemcitabine; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.